Wiping its slate ahead of BMS buy, Celgene to pay $117M in Revlimid antitrust settlements
admin 1st August 2019 Uncategorised 0With Celgene making the big move under Bristol-Myers Squibb’s umbrella, the drugmaker is looking to clear its books before the merger. Two antitrust settlements totaling more than $100 million will cross a couple of legal problems off its list. More:
read more